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the survival of the HT29 cell line (human colorectal cancer cells) and 
on the MRC5 cell line(human fetal lung fibroblasts). Overall irradiation 
time was for four days,once per day. Cell viability was tested by dye 
exclusion test (DET) using trypan blue dye, 24 hours after last 
irradiation session and the total cell number was estimated. Both cell 
lines were irradiated using phantom constructed specially for this 
experiment. Obtained data were processed in STATISTICA ver. 10 
software and basic statistical calculations were performed. 
Results: The low-doses of 0.03Gy and 0.05Gy given alone every day 
during four day period did not have any significant effect on both cell 
lines, while 0.07Gy significantly reduced the cell survival. Same doses 
applied every day two hours before the 2.0Gy fraction, in four days 
overall treatment time, gave different response. The low-dose of 0.05 
Gy led to a significantly induced radiosensitivity in HT29 cells, but not 
in MRC5 cells, while 0.07Gy encreased even more the radiosensitivity 
in human colorectal cancer cells. Contrary, same pre-irradiation dose 
led to a significant radioresistancy in MRC5 cells. 
Conclusions: The pre-irradiation doses of 0.05 and 0.07Gy prior to the 
2Gy fraction increase cell killing in human colorectal cancer cells, and 
at the same time have no significant effect on the survival of human 
fetal lung fibroblasts. Even though these results represent promising 
effect of applied low-dose pre-irradiation with 2Gy fraction 
afterwards, these findings should be proved in vivo, and finally 
implemented as method of choice in radiotherapy treatment. 
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Purpose/Objective: Main radiotherapy problem of cancer treatment is 
side-effect as a result of high dose of radiation. All of the modern 
apparatus for cancer therapy are not enough efficient when low-doses 
applying. It related with the biological sensitivity and reaction of 
tumor cells on radiation. Biological effects could be increased by using 
pulse-modulated radiation. It could allowed to significantly decrease 
radiation dose with saving antitumor efficacy. The source of low-dose 
repetitively pulsed X-ray radiation was first developed and created at 
the Institute of high-current electronics (Russia). 
Materials and Methods: 'Sinus-150' as a generator of pulse periodic X-
ray was applied. A high-voltage pulse had a half-height duration of 4 
ns and amplitude of 260 kV. The calculated photon energy spectrum 
had a maximum at 90 keV, and most of the quantum flux was the 60-
200 keV range. Dose per pulse was 0.3 mR, absorbed dose were 0.12; 
0.2 and 0.5 Gy for 2-time irradiation (day 6 and 9). Solid-type of Lewis 
lung carcinoma was prepared by intramuscularly transplantation of 3 × 
106 cells into the hind limb of C57BL/6 female mice. Tumor volumes 
were measured with calipers and a volume calculated (L+W+W/2). 
The metastases of the lung were counted using a stereoscopic 
microscope. 
Results: Low-dose pulsed X-ray inhibits growth of Lewis lung 
carcinoma cells at all experimental groups. Irradiation with absorbed 
dose 0.12 Gy affects 69 % of tumor inhibition, 0.2 Gy – 56 % and 0.5 Gy 
up to 46 % compare to control group. Inhibition of metastasis growth 
(by square of colonies) was highest in group 0.5 Gy (72 %) and lowest 
at 0.2 Gy absorbed dose (58 %). Applying 0.12 Gy produced 68 % 
decreasing of metastatic colonies square. Same time, index inhibition 
of metastasis (by number of colonies) was highest both in groups 
irradiated with 0.12 and 0.5 Gy (84-85 %) and only 67 % observed in 
group with absorbed dose 0.2 Gy. 
Conclusions: Pulse regime increase antitumor efficacy of low dose X-
ray up to 50 - 70 % and antimetastatic action up to 60 – 80 %. Similar 
effects of non-pulsed X-ray achieved when the absorbed dose exceed 
10 – 20 Gy. 
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Purpose/Objective: To Assess the impact of Personalized Care on 
Treatment Compliance in Cancer Patients  
Materials and Methods: During Jan. 2010 to Jan.2011, 161 patients 
with histologically proven cancer were randomized in two arms: 
study- where patients were provided with personalized care approach, 
patient centred care with requisite related information, whereas 
control arm patients were managed in conventional manner as 
prevalent within the department. All patients were treated as per 
merit of the case and according to departmental policy. Patients were 
evaluated for treatment compliance to the scheduled plan in terms of 
treatment completions and treatment interruptions, dropout rates 
and follow-up rates at the end of 3 months.  
Results: N=161,study- 78, Control- 81; Age: 47.5years (mean), Range-
10-70 yrs; Sex: M:F-1:1.4; Marital status:Married-99%; 
Rural/Urban:Rural-75%; Religion:Hindu-92%; Literacy-39%; 
Occupations: housewives-47%, manual workers-45% (including farmers 
and carpenters), professionals-8%; types of family: joint families-
60%;Referral pattern: within hospital-58%; Sites: Cervix-37%, Head and 
Neck-32%, Breast-8%, GI-7%, brain-4% and others-12%;stage: I=7%, II-
30%, III-21%, IV-31%, stage unknown-11%; Intent of treatment: Radical-
69%,Postoperative-24%, Palliative -7%. Seventy percent of the patients 
completed the prescribed treatment (112/161). The rate of 
completion of treatment in study arm was better than control arm 
(78% vs. 61%) (P=0.02). Of the remaining 49 patients, 16/161 (10%) 
patients were dropped out and 33/161 (20%) patients were not came 
for scheduled treatment. The drop-out rate was similar in both 
control and study arm (10%) while the percent of patients not came 
for treatment was much lower in study arm (12% vs. 29%) (P= 0.011). 
The percentage of patients experiencing treatment interruption in 
those who completed treatment was lower in study arm (12% vs. 15%). 
Study armhad higher number of patients under follow up after 3 
months: 54 (69%) vs.44(53 %).  
Conclusions: The use of personalized care, providing requisite related 
information, communication provision, and supportive care may 
improve treatment compliance in terms of better treatment 
completions, lesser dropouts, low treatment interruptions and better 
follow up.  
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Purpose/Objective: To evaluate and control breakthrough pain (BP) 
episodes in advanced cancer patients (ACP) undergoing radiotherapy 
during proceedings and maneuvers necessary to receive treatment, 
and assess the ability of Fentanyl pectin nasal citrate (FPNC) to 
control these episodes. 
Materials and Methods: Twelve patients with severe BP associated to 
routine radiotherapy procedures and maneuvers were selected to 
receive FPNC for pain relief. Most patients (10/12) suffered from bone 
metastases and showed a low Karnovsky performance status (30-70%). 
BP intensity was evaluated by Visual Analog Scale before and after the 
procedures that triggered it. All patients were already receiving an 
opioid basal treatment at total dose equivalent to 40-80 mg morphine. 
BP was treated before the procedure with a dose of 100-400 µg of 
FPNC. Data related to tolerance, pain relief, onset of the relief and 
efficient dose to allow the procedure were collected. 
Results: In all patients, BP score was reduced at least to 50% after 13 
min (5-30 min) of fentanyl administration. Pain relief started after 7 
min (5-15 min) and the duration of the effect permitted the normal 
procedure development. All patients reported pain control with a dose 
of 200 μg of FPNC except one patient who required progressive doses 
till 600 μg. Five patients reported minor undesirable effects related to 
the FPNC administration. 
Conclusions: Procedures and maneuvers necessary to apply 
radiotherapy treatment in ACP may provoke in some of them severe 
BP episodes, so a simple, rapid and strong analgesic is needed. FPNC 
offers a rapid absorption and pain relief, being particularly efficient 
and well accepted in these patients. This relief allows the completion 
of necessary procedures to administrate treatment without adding 










   
